These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

59 related items for PubMed ID: 7553066

  • 1. HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2.
    Rubin JT, Day R, Duquesnoy R, Simonis B, Adams S, Lee J, Lotze MT.
    Ther Immunol; 1995 Feb; 2(1):1-6. PubMed ID: 7553066
    [Abstract] [Full Text] [Related]

  • 2. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy.
    Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, Balkissoon J, Rosenberg SA, Parkinson DR.
    Cancer Res; 1992 Dec 01; 52(23):6561-6. PubMed ID: 1423301
    [Abstract] [Full Text] [Related]

  • 3. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS, White DE, Hurst R, Rosenberg SA, Yang JC.
    Cancer J Sci Am; 1998 Dec 01; 4(2):86-93. PubMed ID: 9532410
    [Abstract] [Full Text] [Related]

  • 4. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy.
    Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL.
    Clin Cancer Res; 1996 Aug 01; 2(8):1263-74. PubMed ID: 9816296
    [Abstract] [Full Text] [Related]

  • 5. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM.
    J Urol; 2001 Jul 01; 166(1):68-72. PubMed ID: 11435825
    [Abstract] [Full Text] [Related]

  • 6. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
    Royal RE, Steinberg SM, Krouse RS, Heywood G, White DE, Hwu P, Marincola FM, Parkinson DR, Schwartzentruber DJ, Topalian SL, Yang JC, Rosenberg SA.
    Cancer J Sci Am; 1996 Jul 01; 2(2):91-8. PubMed ID: 9166506
    [Abstract] [Full Text] [Related]

  • 7. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
    Sun Y, Jurgovsky K, Möller P, Alijagic S, Dorbic T, Georgieva J, Wittig B, Schadendorf D.
    Gene Ther; 1998 Apr 01; 5(4):481-90. PubMed ID: 9614572
    [Abstract] [Full Text] [Related]

  • 8. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
    Ricaniadis N, Kataki A, Agnantis N, Androulakis G, Karakousis CP.
    Eur J Surg Oncol; 2001 Feb 01; 27(1):88-93. PubMed ID: 11237497
    [Abstract] [Full Text] [Related]

  • 9. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ, Martin D, Elder E, Storkus WJ, Lotze MT.
    Clin Cancer Res; 1996 Jan 01; 2(1):87-95. PubMed ID: 9816095
    [Abstract] [Full Text] [Related]

  • 10. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
    Lacreusette A, Lartigue A, Nguyen JM, Barbieux I, Pandolfino MC, Paris F, Khammari A, Dréno B, Jacques Y, Blanchard F, Godard A.
    J Pathol; 2008 Dec 01; 216(4):451-9. PubMed ID: 18798220
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity.
    Lotze MT, Shurin M, Esche C, Tahara H, Storkus W, Kirkwood JM, Whiteside TL, Elder EM, Okada H, Robbins P.
    Cancer J Sci Am; 2000 Feb 01; 6 Suppl 1():S61-6. PubMed ID: 10685662
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HLA class II polymorphisms in Spanish melanoma patients: homozygosity for HLA-DQA1 locus can be a potential melanoma risk factor.
    Planelles D, Nagore E, Moret A, Botella-Estrada R, Vila E, Guillén C, Montoro JA.
    Br J Dermatol; 2006 Feb 01; 154(2):261-6. PubMed ID: 16433795
    [Abstract] [Full Text] [Related]

  • 15. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.
    Quaglino P, Osella-Abate S, Cappello N, Ortoncelli M, Nardò T, Fierro MT, Cavallo F, Savoia P, Bernengo MG.
    Melanoma Res; 2007 Apr 01; 17(2):75-82. PubMed ID: 17496782
    [Abstract] [Full Text] [Related]

  • 16. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R, Ronteltap C, Heuveling M, Debets R, Bolhuis R.
    Gene Ther; 2005 Jan 01; 12(2):140-6. PubMed ID: 15496961
    [Abstract] [Full Text] [Related]

  • 17. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
    Bettinotti MP, Kim CJ, Lee KH, Roden M, Cormier JN, Panelli M, Parker KK, Marincola FM.
    J Immunol; 1998 Jul 15; 161(2):877-89. PubMed ID: 9670966
    [Abstract] [Full Text] [Related]

  • 18. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
    Ogasawara M, Rosenberg SA.
    Cancer Res; 1993 Aug 01; 53(15):3561-8. PubMed ID: 8101762
    [Abstract] [Full Text] [Related]

  • 19. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J.
    Clin Cancer Res; 2005 Feb 01; 11(3):1237-46. PubMed ID: 15709194
    [Abstract] [Full Text] [Related]

  • 20. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE.
    Cancer J Sci Am; 2000 Feb 01; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.